PQ 912

Drug Profile

PQ 912

Alternative Names: PQ-912

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Probiodrug
  • Developer Covance; Probiodrug
  • Class Antidementias; Neuroprotectants; Small molecules
  • Mechanism of Action Glutaminyl-peptide cyclotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Preclinical Huntington's disease; Inflammation

Most Recent Events

  • 11 Jun 2017 First line adverse events, efficacy and pharmacodynamics data from phase IIa trial in Alzheimer's disease released by Probiodrug
  • 16 May 2017 Pharmacodynamics data from a preclinical study in Alzheimer's disease released by Probiodrug
  • 12 May 2017 Efficacy data from a phase IIa trial in Alzheimer's disease released by Probiodrug
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top